Thompson JE, Sridhar AN, Shaw G, Rajan P, Mohammed A, Briggs TP, Nathan S, Kelly JD et al.(2020). Peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation. BMC urology vol. 20, (1)
Lauria A, Peirone S, Giudice MD, Priante F, Rajan P, Caselle M, Oliviero S, Cereda M(2020). Identification of altered biological processes in heterogeneous RNA-sequencing data by discretization of expression profiles. Nucleic Acids Research vol. 48, (4) 1730-1747.
Sehmbi AS, Sridhar AN, Sahadevan K, Rai BP, Nwangwu P, Mohammed A, Freeman A, Mottrie A et al.(2020). Early outcomes of robot-assisted radical prostatectomy following completion of a structured training curriculum: a single surgeon cohort study. Journal of Clinical Urology
Xu L, Mao X, Grey A, Scandura G, Guo T, Burke E, Marzec J, Abdu S et al.(2020). Reply by Authors. The Journal of urology vol. 203, (1) 81-82.
De Laere B, Crippa A, Ghysel C, Ost P, Rajan P, Eklund M, Dirix L, Gronberg H et al. (2019). Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer. ANNALS OF ONCOLOGY. vol. 30,
Xu L, Mao X, Grey A, Scandura G, Guo T, Burke E, Marzec J, Abdu S et al.(2019). Noninvasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells. The Journal of Urology vol. 203, 101097JU000000000000-101097JU000000000000.
Guo T, Wang Y, Mao X, Xu L, Marzec J, Burke E, Scandura G, Stankiewicz E et al. (2019). Investigation of plasma exosomal miRNA as a biomarker and its potential function in prostate cancer castration resistant development. CANCER RESEARCH. vol. 79,
Thompson JE, Sridhar AN, Tan WS, Freeman A, Haider A, Allen C, Moore CM, Orczyk C et al.(2019). Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound. J Urol vol. 201, (6) 1134-1143.
De Laere B, Rajan P, Grönberg H, Dirix L, Lindberg J, CORE-ARV-CTC and ProBIO Investigators(2019). Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol
Heavey S, Costa H, Pye H, Burt EC, Jenkinson S, Lewis GR, Bosshard-Carter L, Watson F et al.(2019). PEOPLE: PatiEnt prOstate samPLes for rEsearch, a tissue collection pathway utilizing magnetic resonance imaging data to target tumor and benign tissue in fresh radical prostatectomy specimens. Prostate vol. 79, (7) 768-777.
De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J et al.(2019). TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer. Clinical Cancer Research vol. 25, (6) 1766-1773.
Mayrhofer M, De Laere B, Whitington T, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W et al.(2018). Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Medicine vol. 10, (1)
Guo T, Wang Y, Mao X, Xu L, Marzec J, Burke E, Shaw G, Hines J et al. (2018). Investigation of exosomal miRNA as biomarker for prostate cancer castration resistance development. BRITISH JOURNAL OF CANCER. Conference: NCRI Cancer Conferences vol. 119, 32-32.
Munkley J, Maia TM, Ibarluzea N, Livermore KE, Vodak D, Ehrmann I, James K, Rajan P et al.(2018). Androgen-dependent alternative mRNA isoform expression in prostate cancer cells. F1000Research vol. 7, 1189-1189.
Foxler DE, Bridge KS, Foster JG, Grevitt P, Curry S, Shah KM, Davidson KM, Nagano A et al.(2018). A HIF-LIMD1 negative feedback mechanism mitigates the pro-tumorigenic effects of hypoxia. EMBO Mol Med
Rajan P, Hagman A, Sooriakumaran P, Nyberg T, Wallerstedt A, Adding C, Akre O, Carlsson S et al.(2018). Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up. European Urology Focus vol. 4, (3) 351-359.
Lamb BW, Rajan P(2018). The practicing urologists’ guide to clinical research. Journal of Clinical Urology
Rajan P, Sooriakumaran P, Nyberg T, Akre O, Carlsson S, Egevad L, Steineck G, Wiklund NP(2017). Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study. J Clin Oncol vol. 35, (31) 3566-3574.
Munkley J, Livermore K, Rajan P, Elliott DJ(2017). RNA splicing and splicing regulator changes in prostate cancer pathology. Human Genetics vol. 136, (9) 1143-1154.
Munkley J, McClurg UL, Livermore KE, Ehrmann I, Knight B, Mccullagh P, Mcgrath J, Crundwell M et al.(2017). The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration. Sci Rep vol. 7, (1) 5249-5249.
Munkley J, Vodak D, Livermore KE, James K, Wilson BT, Knight B, Mccullagh P, Mcgrath J et al.(2016). Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability. EBioMedicine
Stockley J, Markert E, Zhou Y, Robson CN, Elliott DJ, Lindberg J, Leung HY, Rajan P(2015). The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7. Scientific Reports vol. 5, (1) Article 13426,
Rajan P, Frew JA, Wilson JM, Azzabi AST, McMenemin RM, Stockley J, Soomro NA, Durkan G et al.(2015). Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non–castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations vol. 33, (8) 337.e1-337.e6.
Munkley J, Lafferty NP, Kalna G, Robson CN, Leung HY, Rajan P, Elliott DJ(2015). Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells. BMC Cancer vol. 15, (1) Article 9,
Munkley J, Livermore KE, McClurg UL, Kalna G, Knight B, McCullagh P, McGrath J, Crundwell M et al.(2015). The PI3K regulatory subunit gene PIK3R1 is under direct control of androgens and repressed in prostate cancer cells. Oncoscience vol. 2, (9) 755-764.
Munkley J, Oltean S, Vodák D, Wilson BT, Livermore KE, Zhou Y, Star E, Floros VI et al.(2015). The androgen receptor controls expression of the cancerassociated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget vol. 6, (33) 34358-34374.
Rajan P, Stockley J, Sudbery IM, Fleming JT, Hedley A, Kalna G, Sims D, Ponting CP et al.(2014). Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer. BMC Cancer vol. 14, (1) Article 977,
Rajan P, Sudbery IM, Villasevil MEM, Mui E, Fleming J, Davis M, Ahmad I, Edwards J et al.(2014). Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy. European Urology vol. 66, (1) 32-39.
Stockley J, Villasevil MEM, Nixon C, Ahmad I, Leung HY, Rajan P(2014). The RNA-binding protein hnRNPA2 regulates β-catenin protein expression and is overexpressed in prostate cancer. RNA Biology vol. 11, (6) 755-765.
Lamb BW, Rajan P(2014). Clinical Research Toolkit for Urologists. Journal of Clinical Urology vol. 9, (3)
Munkley J, Rajan P, Laferty NP, Dalgliesh C, Jackson RM, Robson CN, Leung HY, Elliott DJ(2013). A novel androgen-regulated isoform of the TSC2 tumour suppressor gene increases cell proliferation. Oncotarget vol. 5, (1) 131-139.
Rajan P, Gaughan L, Dalgliesh C, El-Sherif A, Robson CN, Leung HY, Elliott DJ(2008). The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor. The Journal of Pathology vol. 215, (1) 67-77.